Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which was unveiled at the American College of Cardiology (ACC) conference.
Emphasizing improved cardiac imaging workflow efficiency, Philips introduced the portable Compact Ultrasound 5500CV device at the recent American College of Cardiology (ACC) conference.
The company said the Compact Ultrasound 5500CV’s AI-driven Auto Measure function provides 50 percent faster two-dimensional and Doppler cardiac measurements.
The Compact Ultrasound 5500CV device provides 50 percent faster two-dimensional and Doppler cardiac measurements, according to Philips, the manufacturer of the device. (Image courtesy of Philips.)
Offering full compatibility with X7-2t and X8-2T transesophogeal echocardiography (TEE) transducers, the Compact Ultrasound 5500CV device facilitates high-resolution ultrasound images for catheter-based cardiac procedures, according to Philips. Employing mMatrix transducers, Philips pointed out the Compact Ultrasound 5500CV platform provides a significant advantage over two-dimensional ultrasound methods by enabling simultaneous capture of two cross-sectional views with a single probe pass.
“By bringing premium-level technology into a compact, accessible solution, we empower clinicians to deliver fast, accurate diagnoses across diverse care settings, improving patient outcomes and expanding access to advanced cardiac imaging,” noted David Handler, the business leader of cardiology ultrasound at Philips.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.